The 10 February US Food and Drug Administration advisory committee review of Eli Lilly and Company/Innovent Biologics, Inc.’s sintilimab kicked off with an unusually lengthy set of introductory remarks by Division of Oncology Products 2 Director Harpreet Singh, intended in part to underscore the unusual nature of the meeting.
“Today’s ODAC will not follow the traditional paradigm of assessing the benefit/risk profile of a single drug,” Singh told the...








